Oral Contraceptives Interactions

Do not use hormonal contraceptives with mifepristone.

Source: NLP:mifepristone

Mitotane decreases the levels and efficacy of hormonal contraceptives. Avoid concomitant use.

Source: NLP:mitotane

Concomitant use may increase thrombotic risk associated with combined hormonal contraceptives due to tranexamic acid's antifibrinolytic properties.

Source: NLP:tranexamic acid

Decreased hormonal exposure during and for 28 days after aprepitant. Use alternative contraception methods during treatment and for 1 month after.

Source: NLP:aprepitant

Decreased efficacy possibly resulting in pregnancy and breakthrough bleeding; use a different or additional form of contraception.

Source: NLP:bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride

Decreased hormonal exposure during and for 28 days after administration. Use alternative or back-up contraception methods.

Source: NLP:fosaprepitant

Decreased hormonal exposure during administration and for 28 days after last dose. Effective alternative or back-up contraception methods recommended.

Source: NLP:fosaprepitant dimeglumine

Coadministration associated with 55% decrease in lorazepam half-life and 50% increase in volume of distribution, resulting in 3.7-fold increase in plasma concentrations.

Source: NLP:lorazepam

May reduce effectiveness of oral contraceptives; additional barrier contraceptive methods must be used.

Source: NLP:mycophenolic acid

Repotrectinib decreases progestin or estrogen exposure, reducing contraceptive effectiveness. Avoid concomitant use; use nonhormonal contraception instead.

Source: NLP:repotrectinib

Concomitant use is not recommended. If clinically necessary, initiate tizanidine with 2 mg dose and titrate in 2-4 mg steps daily.

Source: NLP:tizanidine

CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring

Source: NLP:warfarin

CYP1A2 inhibitor that increases warfarin effect and INR; requires close INR monitoring.

Source: NLP:warfarin sodium

Oral contraceptives produce hyperglycemia and may lead to loss of blood glucose control in patients receiving Acarbose. Close observation for loss of glucose control is recommended.

Source: NLP:acarbose

Increased alprazolam maximum plasma concentration by 18%, decreased clearance by 22%, and increased half-life by 29%.

Source: NLP:alprazolam

May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive.

Source: NLP:amlodipine and atorvastatin

Amoxicillin may reduce efficacy of combined oral estrogen/progesterone contraceptives by affecting intestinal flora and lowering estrogen reabsorption.

Source: NLP:amoxicillin

May reduce efficacy of combined oral estrogen/progesterone contraceptives by affecting intestinal flora and lowering estrogen reabsorption.

Source: NLP:amoxicillin and clavulanate potassium

May be less effective with increased breakthrough bleeding may occur.

Source: NLP:ampicillin

Effectiveness of steroidal contraceptives may be reduced when used with armodafinil via CYP3A4/5 induction. Alternative or concomitant contraception methods recommended.

Source: NLP:armodafinil

May increase plasma levels of norethindrone and ethinyl estradiol; consider this effect when selecting an oral contraceptive.

Source: NLP:atorvastatin calcium

Oral contraceptives may decrease hepatic metabolism of certain corticosteroids, increasing their effect.

Source: NLP:betamethasone acetate and betamethasone sodium phosphate

Bexarotene may induce CYP3A4 and reduce plasma concentrations of hormonal contraceptives, reducing contraceptive efficacy.

Source: NLP:bexarotene

Cefuroxime axetil may affect gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.

Source: NLP:cefuroxime axetil

Increases biliary cholesterol secretion and may counteract the effectiveness of chenodiol.

Source: NLP:chenodiol

Effectiveness may be diminished as clobazam is a weak CYP3A4 inducer and some hormonal contraceptives are metabolized by CYP3A4.

Source: NLP:clobazam

Moderate or weak CYP1A2 inhibitor that may increase clozapine levels. Monitor patients closely and consider dose reduction if necessary.

Source: NLP:clozapine

Increase cyclosporine concentrations. Dosage adjustment essential.

Source: NLP:cyclosporine

Deferasirox may induce CYP3A4 resulting in decreased hormonal contraceptive concentration. Monitor for reduced effectiveness.

Source: NLP:deferasirox

Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.

Source: NLP:demeclocycline

Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.

Source: NLP:demeclocycline hydrochloride

Oral contraceptives may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

Source: NLP:dexamethasone

Estrogens may decrease hepatic metabolism of dexamethasone, thereby increasing its effect.

Source: NLP:dexamethasone 1.5 mg

Oral contraceptives may decrease hepatic metabolism of dexamethasone, thereby increasing its effect.

Source: NLP:dexamethasone intensol

Concurrent use of tetracycline may render oral contraceptives less effective.

Source: NLP:doxycycline

Concurrent use of tetracycline may render oral contraceptives less effective.

Source: NLP:doxycycline hyclate

May produce hyperglycemia and lead to loss of glycemic control; monitor closely.

Source: NLP:empagliflozin, metformin hydrochloride

Oral contraceptives increase folate turnover and urinary loss.

Source: NLP:folic acid

Oral contraceptives may produce hyperglycemia and lead to loss of control of glyburide. Patients should be closely observed for loss of control.

Source: NLP:glyburide

May reduce glucose-lowering effect of glimepiride, leading to worsening glycemic control.

Source: NLP:glimepiride

Oral contraceptives may produce hyperglycemia and lead to loss of glycemic control. Patient should be observed closely for loss of control when initiated or withdrawn.

Source: NLP:glipizide

Griseofulvin may enhance metabolism of the estrogen component, reducing contraceptive effectiveness and causing menstrual irregularities.

Source: NLP:griseofulvin

Oral contraceptives may decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Source: NLP:hydrocortisone sodium succinate

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Source: NLP:insulin aspart

May decrease blood glucose lowering effect. Dose adjustment and increased glucose monitoring may be required.

Source: NLP:insulin aspart-szjj

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Source: NLP:insulin degludec

May decrease blood glucose lowering effect. Dosage increases and increased glucose monitoring may be required.

Source: NLP:insulin glargine

May decrease blood glucose lowering effect; dose adjustment and increased glucose monitoring may be required.

Source: NLP:insulin human

May decrease blood glucose lowering effect. Dose increases and increased glucose monitoring may be required.

Source: NLP:insulin lispro-aabc

Estrogen-containing oral contraceptives increase serum thyroxine-binding globulin, potentially decreasing free levothyroxine. Patients without functioning thyroid may require increased thyroid dose.

Source: NLP:levothyroxine, liothyronine

Oral contraceptives may produce hyperglycemia and lead to loss of glycemic control. Close monitoring of glycemic control is recommended.

Source: NLP:linagliptin and metformin hydrochloride

Estrogens may decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Source: NLP:ammonia, lidocaine hydrochloride, triamcinolone acetonide, povidone-iodine

Produce hyperglycemia and may lead to loss of glycemic control when used with metformin.

Source: NLP:metformin

May produce hyperglycemia and lead to loss of glycemic control. Monitor patient closely for loss of blood glucose control.

Source: NLP:metformin er 500 mg

Drugs that produce hyperglycemia and may lead to loss of glycemic control; monitor blood glucose.

Source: NLP:metformin hydrochloride

May produce hyperglycemia and lead to loss of glycemic control during metformin therapy; monitor blood glucose.

Source: NLP:metformin hydrochloride extended-release tablets

May produce hyperglycemia and lead to loss of glycemic control when used with metformin.

Source: NLP:metformin hydrochloride tablet

Oral contraceptives may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

Source: NLP:methylprednisolone acetate

May decrease hepatic metabolism of certain corticosteroids, thereby increasing their effect.

Source: NLP:methylprednisolone sodium succinate

Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.

Source: NLP:minocycline hydrochloride

Drug interaction study conducted; no dose adjustment recommended when coadministered with mirabegron.

Source: NLP:mirabegron

Effectiveness of steroidal contraceptives may be reduced when used with modafinil. Alternative or concomitant contraception methods recommended during treatment and for one month after discontinuation.

Source: NLP:modafinil

Mycophenolate mofetil may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended.

Source: NLP:mycophenolate mofetil

Moderate CYP3A4 inhibitor that may increase nimodipine plasma concentration and blood pressure lowering effect. Blood pressure monitoring and dose reduction of nimodipine may be necessary.

Source: NLP:nimodipine

Oxcarbazepine may decrease the effectiveness of hormonal contraceptives, including oral and implant formulations.

Source: NLP:oxcarbazepine

Oral contraceptives may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

Source: NLP:prednisolone sodium phosphate

Estrogens in contraceptives may decrease hepatic metabolism of corticosteroids, thereby increasing their effect.

Source: NLP:prednisone

Serum folate levels may be depressed by oral contraceptive therapy.

Source: NLP:prenatal multivitamin tablet and combination omega-3 softgel/mineral capsule

CYP1A2 inhibitor that may increase riluzole exposure and risk of riluzole-associated adverse reactions.

Source: NLP:riluzole

Rufinamide may reduce effectiveness of hormonal contraceptives; additional non-hormonal contraception recommended.

Source: NLP:rufinamide

SILTUXIMAB may increase metabolism of oral contraceptives via CYP3A4, potentially decreasing effectiveness. Exercise caution and monitor effectiveness.

Source: NLP:siltuximab

May produce hyperglycemia and lead to loss of glycemic control. Monitor blood glucose closely during concomitant use.

Source: NLP:sitagliptin and metformin hydrochloride

Chronically administered oral contraceptives may enhance neuromuscular blocking effect by reducing plasma cholinesterase activity.

Source: NLP:succinylcholine chloride

Concurrent use of tetracycline may render oral contraceptives less effective.

Source: NLP:tetracycline hydrochloride

Estrogen-containing formulations increase serum thyroxine-binding globulin (TBg), decreasing free levothyroxine (T4) in patients without functioning thyroid glands. May require increased thyroid dose.

Source: NLP:thyroid, porcine

Concurrent use of tigecycline with oral contraceptives may render oral contraceptives less effective.

Source: NLP:tigecycline

Moderate CYP1A2 inhibitor; concomitant use not recommended but if necessary, monitor for hypotension, bradycardia, or excessive drowsiness and reduce tizanidine dosage.

Source: NLP:tizanidine hydrochloride

Concomitant use not recommended; if necessary, monitor for hypotension, bradycardia, or excessive drowsiness and reduce or discontinue tizanidine.

Source: NLP:tizanidne hydrochloride

Exercise caution with tocilizumab coadministration as CYP3A4 inhibition may decrease oral contraceptive effectiveness.

Source: NLP:tocilizumab

Decreased contraceptive efficacy and increased breakthrough bleeding, especially at doses greater than 200 mg/day. Effect may occur without breakthrough bleeding.

Source: NLP:topiramate

Oral contraceptive estrogens may decrease hepatic metabolism of corticosteroids, increasing their effect.

Source: NLP:triamcinolone acetonide

Coadministration increased maximum plasma concentration by 6%, decreased clearance by 32%, and increased half-life by 16%.

Source: NLP:triazolam

Increase hepatic cholesterol secretion and may counteract the effectiveness of ursodiol.

Source: NLP:ursodiol

Increase hepatic cholesterol secretion and encourage cholesterol gallstone formation, potentially counteracting ursodiol effectiveness.

Source: NLP:usodiol

Levetiracetam did not influence pharmacokinetics of oral contraceptive containing ethinyl estradiol and levonorgestrel or hormone levels; oral contraceptive did not affect levetiracetam pharmacokinetics.

Source: NLP:levetiracetam

No dose adjustment needed when co-administered with montelukast sodium.

Source: NLP:montelukast

No dose adjustment needed when co-administered with montelukast sodium.

Source: NLP:montelukast sodium